Cargando…

Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: A subanalysis of the ANAFIE Registry

The real-world status of proton pump inhibitor (PPI) use in patients with atrial fibrillation (AF) receiving antithrombotic treatment is largely unknown. The All Nippon AF In the Elderly (ANAFIE) Registry, a prospective, multicenter, observational study, aimed to determine treatment patterns, risk f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mizokami, Yuji, Yamamoto, Takatsugu, Atarashi, Hirotsugu, Yamashita, Takeshi, Akao, Masaharu, Ikeda, Takanori, Koretsune, Yukihiro, Okumura, Ken, Shimizu, Wataru, Tsutsui, Hiroyuki, Toyoda, Kazunori, Hirayama, Atsushi, Yasaka, Masahiro, Yamaguchi, Takenori, Teramukai, Satoshi, Kimura, Tetsuya, Kaburagi, Jumpei, Takita, Atsushi, Inoue, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644054/ https://www.ncbi.nlm.nih.gov/pubmed/33151969 http://dx.doi.org/10.1371/journal.pone.0240859

Ejemplares similares

Oral Anticoagulant Use in Elderly Japanese Patients With Non-Valvular Atrial Fibrillation　― Subanalysis of the ANAFIE Registry ―
por: Akao, Masaharu, et al.
Publicado: (2020)

Background characteristics and anticoagulant usage patterns of elderly non-valvular atrial fibrillation patients in the ANAFIE registry: a prospective, multicentre, observational cohort study in Japan
por: Yasaka, Masahiro, et al.
Publicado: (2021)

High prevalence of masked uncontrolled morning hypertension in elderly non‐valvular atrial fibrillation patients: Home blood pressure substudy of the ANAFIE Registry
por: Kario, Kazuomi, et al.
Publicado: (2020)

Clinical phenotypes of older adults with non-valvular atrial fibrillation not treated with oral anticoagulants by hierarchical cluster analysis in the ANAFIE Registry
por: Suzuki, Shinya, et al.
Publicado: (2023)

Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry
por: Yamashita, Takeshi, et al.
Publicado: (2021)

Renal Function and Clinical Outcomes Among Elderly Patients With Nonvalvular Atrial Fibrillation From ANAFIE
por: Shimizu, Wataru, et al.
Publicado: (2023)

Coagulation Biomarkers and Clinical Outcomes in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Subcohort Study
por: Koretsune, Yukihiro, et al.
Publicado: (2023)

Oral Anticoagulants in Very Elderly Nonvalvular Atrial Fibrillation Patients With High Bleeding Risks: ANAFIE Registry
por: Okumura, Ken, et al.
Publicado: (2022)

Anticoagulant therapy and home blood pressure-associated risk for stroke/bleeding events in elderly patients with non-valvular atrial fibrillation: the sub-cohort study of ANAFIE registry
por: Kario, Kazuomi, et al.
Publicado: (2023)

Impact of cognitive impairment on clinical outcomes in elderly patients with atrial fibrillation: ANAFIE Registry
por: Nagata, Ken, et al.
Publicado: (2023)

Impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Registry
por: Yoshimoto, Takeshi, et al.
Publicado: (2022)

Impact of glycated hemoglobin on 2-year clinical outcomes in elderly patients with atrial fibrillation: sub-analysis of ANAFIE Registry, a large observational study
por: Terauchi, Yasuo, et al.
Publicado: (2023)

Home Blood Pressure Can Predict the Risk for Stroke/Bleeding Events in Elderly Patients With Nonvalvular Atrial Fibrillation From the ANAFIE Registry
por: Kario, Kazuomi, et al.
Publicado: (2022)

Risk of both intracranial hemorrhage and ischemic stroke in elderly individuals with nonvalvular atrial fibrillation taking direct oral anticoagulants compared with warfarin: Analysis of the ANAFIE registry
por: Shiozawa, Masayuki, et al.
Publicado: (2023)

Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry
por: Kodani, Eitaro, et al.
Publicado: (2018)

Impact of heart rate on adverse events in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry
por: Kodani, Eitaro, et al.
Publicado: (2022)

Predictive ability of visit-to-visit blood pressure indices for adverse events in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry
por: Kodani, Eitaro, et al.
Publicado: (2023)

Predictive ability of creatinine clearance versus estimated glomerular filtration rate for outcomes in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry
por: Kodani, Eitaro, et al.
Publicado: (2020)

Characteristics of Japanese Patients with Nonvalvular Atrial Fibrillation on Anticoagulant Treatment: A Descriptive Analysis of J-dabigatran Surveillance and JAPAF Study
por: Koretsune, Yukihiro, et al.
Publicado: (2019)

Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance
por: Inoue, Hiroshi, et al.
Publicado: (2016)

Impact of Blood Pressure Visit‐to‐Visit Variability on Adverse Events in Patients With Nonvalvular Atrial Fibrillation: Subanalysis of the J‐RHYTHM Registry
por: Kodani, Eitaro, et al.
Publicado: (2020)

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis
por: Ishii, Mitsuru, et al.
Publicado: (2022)

Impact of anemia on the clinical outcomes in elderly patients with atrial fibrillation receiving apixaban: J-ELD AF registry subanalysis
por: Tanaka, Nobuaki, et al.
Publicado: (2022)

Factors associated with bleeding events during catheter ablation with uninterrupted periprocedural edoxaban for atrial fibrillation: a subanalysis of the KYU-RABLE study
por: Abe, Ichitaro, et al.
Publicado: (2021)

Clinical Outcomes of Very Elderly Patients With Atrial Fibrillation Receiving On‐label Doses of Apixaban: J‐ELD AF Registry Subanalysis
por: Okada, Masato, et al.
Publicado: (2021)

Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU‐RABLE
por: Shinohara, Tetsuji, et al.
Publicado: (2020)

Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Hisatake, Shinji, et al.
Publicado: (2022)

Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Nakamura, Mashio, et al.
Publicado: (2023)

Clinical phenotypes of patients with non-valvular atrial fibrillation as defined by a cluster analysis: A report from the J-RHYTHM registry
por: Watanabe, Eiichi, et al.
Publicado: (2021)

One-Year Incidences of Venous Thromboembolism, Bleeding, and Death in Patients With Lung Cancer (Cancer-VTE Subanalysis)
por: Awano, Nobuyasu, et al.
Publicado: (2022)

Prognostication of Patients with Pulmonary Thromboembolism with and without Residual Deep Vein Thrombosis: A Subanalysis of the J’xactly Study
por: Yamada, Norikazu, et al.
Publicado: (2023)

Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial
por: Yoshida, Tetsuro, et al.
Publicado: (2022)

Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE–AF Randomized Clinical Trial
por: Kuroda, Masaru, et al.
Publicado: (2022)

Impact of baseline blood pressure on adverse outcomes in Japanese patients with non-valvular atrial fibrillation: the J-RISK AF
por: Kodani, Eitaro, et al.
Publicado: (2022)

Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial
por: Hoshino, Haruhiko, et al.
Publicado: (2021)

Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation
por: Yamato, Hiroshi, et al.
Publicado: (2020)

Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study
por: Koretsune, Yukihiro, et al.
Publicado: (2017)

Incidence of venous thromboembolism and bleeding events in patients with lower extremity orthopedic surgery: a retrospective analysis of a Japanese healthcare database
por: Fuji, Takeshi, et al.
Publicado: (2017)

Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation: Sub-analysis of the EXPAND Study
por: Uchiyama, Shinichiro, et al.
Publicado: (2018)

Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study
por: Atarashi, Hirotsugu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ip68fjsivtqul9stffur79fvif